Table:
Number of studies including most commonly used adjuvants/immunostimulants
Adjuvant	Phase 2	Phase 2/3	Phase 3	Total
GM-CSF	92	1	16	109
Montanide	60	1	5	66
IL-2	53	3	56
KLH	16	8	24
TRICOM	10	3	13
QS21	5	1	6
Poly-ICLC	8	0	0	8

Express the table as Markdown code.

| <COLSPAN=5> Number of studies including most commonly used adjuvants/immunostimulants | 
 | Adjuvant | Phase 2 | Phase 2/3 | Phase 3 | Total | 
 | --- | --- | --- | --- | --- | 
 | GM-CSF | 92 | 1 | 16 | 109 | 
 | Montanide | 60 | 1 | 5 | 66 | 
 | IL-2 | 53 |  | 3 | 56 | 
 | KLH | 16 |  | 8 | 24 | 
 | TRICOM | 10 |  | 3 | 13 | 
 | QS21 | 5 |  | 1 | 6 | 
 | Poly-ICLC | 8 | 0 | 0 | 8 |